The National Institutes of Health recently announced two funding opportunities for research initiatives with potential microRNA and non-coding RNA aspects including one related to the treatment of HIV-1 and another to lung development research.

With the first opportunity, the NIH is aiming to address the problem of HIV-1 persistence following highly active anti-retroviral therapy, which suppresses HIV RNA levels in plasma and cerebral spinal fluid, yet does not completely eliminate the virus due to sequestration in cellular and tissue reservoirs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.